Patent application number | Description | Published |
20110256867 | Method, User Equipment, and System for Network Selection - A method, user equipment (UE) and system relates to communications technologies, and in particular, to a network selection technology for a UE on a mobile communication network. The method includes obtaining a public land mobile network and closed subscriber group identity (PLMN/CSG ID) combination parameter of a network that covers a current location; querying an allowed CSG list according to the PLMN/CSG ID combination parameter; and selecting a network according to a query result. | 10-20-2011 |
20120094629 | SERVICE PROCESSING METHOD, COMMUNICATION DEVICE, AND COMMUNICATION SYSTEM - Embodiments of the present invention disclose a service processing method, a communication device, and a communication system. The service processing method includes: receiving a request message initiated by a user equipment (UE); and changing a current default bearer of the UE according to the received request message, to a bearer corresponding to a service that the UE needs to obtain in a current serving cell. The communication device includes: a generating unit, configured to generate a request message, where the request message carries information indicating a service required by a UE; and a sending unit, configured to send the request message generated by the generating unit to a network side, where the network side changes a current default bearer of the UE according to the information carried in the request message, to a bearer corresponding to a service that the UE needs to obtain in a current serving cell. | 04-19-2012 |
20120100823 | METHOD, SYSTEM, NETWORK SIDE DEVICE, AND UE OF MANAGING CSG MEMBERSHIP - The present invention discloses a method, system, network side device, and UE of managing CSG membership. The method includes: detecting, by a network side, a change of CSG membership of a UE when the UE camps on a CSG cell and establishes a default bearer; and when detecting the change of the CSG membership of the UE, triggering, by the network, a Detach procedure between the network side and the UE by using an existing path between the network side and the UE, and indicating state information about the CSG membership of the UE, where the state information is used to instruct the UE to perform an operation with respect to the change of the CSG membership according to the state information. | 04-26-2012 |
20120182972 | METHOD AND DEVICE FOR ESTABLISHING OR MODIFYING LOCAL IP ACCESS BEARER - A method and device for establishing or modifying a local IP access bearer are provided by the embodiments of the present invention, said method includes: a handover request message transmitted by an evolved Node Base station is received, said handover request message carries an evolved Node Base station identifier, said evolved Node Base station identifier is the same as the local packet data network gateway identifier; the local breakout ability of said evolved Node Base station is obtained; according to said evolved Node Base station identifier, the local breakout ability of said evolved Node Base station and the local IP access point name, the local IP access bearer is established or modified between a serving gateway and the local packet data network gateway, said serving gateway is located in the core network or the evolved Node Base station. | 07-19-2012 |
20130116256 | HEXENONE COMPOUNDS AND MEDICAL USE THEREOF - The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof; to a composition comprising a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluent; and also to use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, or preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, or preventing or treating a disease or disorder associated with cardiomyocyte apoptosis. | 05-09-2013 |
20130123300 | UREA COMPOUNDS AND USE THEREOF FOR INHIBITING APOPTOSIS - A compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, is provided. Also, a composition containing a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents, is provided. Further, use of a compound of Formula I, or an isomer, pharmaceutically acceptable salt or solvate thereof for anti-apoptosis is provided, preventing or treating a disease or disorder associated with apoptosis; especially for protecting cardiomyocyte, preventing or treating a disease or disorder associated with cardiomyocyte apoptosis. | 05-16-2013 |
20130158022 | Acrylamide Compounds And Use Thereof For Inhibiting Apoptosis - The present invention relates to a compound of Formula I, or an isomer, pharmaceutically acceptable salt and solvate of the compound, and to a composition comprising the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents. The present invention also relates to use of the compound of Formula I, or the isomer, pharmaceutically acceptable salt and solvate thereof for combating apoptosis, preventing or treating a disease or disorder associated with apoptosis; and especially use for protecting cardiomyocyte, and for preventing or treating a disease or disorder associated with cardiomyocyte apoptosis. | 06-20-2013 |
20150119430 | Thiazole Compounds and Uses Thereof - The present invention relates to a compound of Formula (I), or an isomer, pharmaceutically acceptable salt and solvate thereof; the present invention further relates to a pharmaceutical composition, which comprises the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier, excipient or diluents; the present invention further relates to the use of the compound of Formula (I), or isomer, pharmaceutically acceptable salt or solvate thereof, for anti-apoptosis, prophylaxis or treatment of a disease or symptom associated with apoptosis, especially for protecting myocardial cells, and prophylaxis or treatment of a disease or symptom associated with cardiomyocyte apoptosis. | 04-30-2015 |